Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1996-12-24
1999-08-03
Moezie, M.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514403, 514850, A61K 3144, A61K 31415
Patent
active
059325895
DESCRIPTION:
BRIEF SUMMARY
DESCRIPTION
This invention relates to an antitussive composition.
More particularly, this invention relates to an oral antitussive composition, characterized in that it comprises a centrally acting antitussive or a pharmaceutically acceptable salt thereof and benzydamine or a pharmaceutically acceptable acid addition salt thereof.
Coughing is a physiological action heplful to free the respiratory tract from foreign substances and from excess secretions. In some cases however, coughing performs no useful purpose, and instead anger the patient or prevent his or her rest or sleep. This leads to the need for administering a drug capable of reducing the recurrence and/or severity of coughing.
Among the many drugs which reduce coughing some act on the central nervous system. Examples of such antitussives are: codeine, dextromethorphan, dihydrocodeine, dimemorfan, noscapine, levopropoxyphene napsylate, carbetapentane, caramiphen, chlophedianol, diphenhydramine, glaucine, benzonatate, hydrocodone and hydromorphone. The most commonly used of these are: codeine, dextromethorphan, dihydrocodeine, dimemorphan and noscapine.
Dextromethorphan is a particularly significant example of a non-narcotic, centrally acting antitussive (The Merck Index, 9th ed., 1976, page 1289, No. 8116). The average dose of dextromethorphan hydrobromide to be given to adults is of 15 to 30 mg, 3-4 times a day (Goodman & Gilman--"le basi farmacologiche della terapia"--8th italian edition, Zanichelli--Bologna). It is available in dragees, tablets, syrups and drops, alone or in association with balsamic-expectorant products.
Benzydamine (The Merck Index, 9th Edition, 1976, page 147, No. 1136) was disclosed for the first time by U.S. Pat. No. 3,318,905 which relates to a group of products having analgesic, anti-inflammatory and muscle relaxant activity. It has been widely utilized in human therapy as hydrochloride. As far as the systemic route is concerned, it is mainly utilized as anti-inflammatory and analgesic agent, by topical route it is however mainly utilized in those pathologies which involve local inflammation such as, for example, myalgia, tendonitis, vulvovaginitis, gingivitis, stomatitis, inflammation of mucosa of the buccal cavity and the like.
It has now unexpectedly been found that benzydamine and pharmaceutically acceptable acid addition salt thereof are capable of shortening the onset time of the action of centrally acting antitussives on the peripheral stimulus of the cough in particular pathologies compared to the antitussive alone.
This unexpected effect has been proved by clinical trials in human.
Therefore, it is a first object of this invention to provide an oral antitussive pharmaceutical composition, characterized in that: of the buccal cavity, and salt thereof and benzydamine or a pharmaceutically acceptable acid addition salt thereof.
For example, dextromethorphan alone performs its action in 20-30 minutes (H. Matthys, B. Bleicher et al.; J. Int. Med. Res., 11, 92-100, 1983).
However, when it is administered in association with benzydamine or a pharmaceutically acceptable acid addition salt thereof, in a pharmaceutical dosage form which allows a significant contact of its components with the mucous membranes of the buccal cavity, it reduces the cough symptom in a much shorter time, that is to say in a few minutes.
Examples of suitable pharmaceutical dosage forms which allow a significant contact of their components with the mucous membranes of the buccal cavity are pastilles, sweets, chewable tablets and chewing gums.
In addition to benzydamine or an acid addition salt thereof, such as hydrochloride, and a centrally acting antitussive or a pharmaceutically acceptable salt thereof, the compositions of this invention comprise a solid or fluid inert diluent or vehicle and, optionally, other additives suitable for pharmaceutical use, and are prepared by conventional techniques.
Examples of suitable additives are sweeteners, flavourings and dyes.
In the composition of this invention, the effective dose of benzydamine and of
REFERENCES:
patent: 5196436 (1993-03-01), Smith
Budavari, S. et al., "The Merck Index" (11.sup.th Ed.) Merck & Co., Inc., Rahway, N.J. (1989), pp. 175-176.
Hartung-Brooks, On Continuing Practice, vol. 17, No. 1 (Jan. 1990) pp. 2-6.
Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A.
Moezie M.
LandOfFree
Antitussive composition containing dextromethorphan and benzydam does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antitussive composition containing dextromethorphan and benzydam, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antitussive composition containing dextromethorphan and benzydam will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-849747